Embolization of liver tumors: Past, present and future

Authors:
  • JSJeswanth Sathyanesan
    Jeswanth Sathyanesan
  • SRSukumar Ramaswami
    Sukumar Ramaswami
  • ALAnand Lakshmanan
    Anand Lakshmanan
  • PSPerumal Senthil-Kumar
    Perumal Senthil-Kumar
  • USUlagendra Perumal Srinivasan
    Ulagendra Perumal Srinivasan
  • RRRavi Ramasamy
    Ravi Ramasamy
  • PRPalaniappan Ravichandran
    Palaniappan Ravichandran

Abstract
Curative therapies for hepatocellular carcinoma (HCC), such as resection and liver transplantation, can only be applied in selected patients with early tumors. More advanced stages require local or systemic therapies. Resection of HCC offers the only hope for cure. Even in patients undergoing resection, recurrences are common. Chemoembolization, a technique combining intra-arterial chemotherapy with selective tumor ischemia, has been shown by randomized controlled trials to be efficacious in the palliative setting. There is now renewed interest in transarterial embolization/transarterial chemoembolization (TACE) with regards to its use as a palliative tool in a combined modality approach, as a neoadjuvant therapy, in bridging therapy before transplantation, for symptomatic indications, and even as an alternative to resection. There have also been rapid advances in the agents being embolized trans-arterially (genes, biological response modifiers, etc.). The current review provides an evidence-based overview of the past, present and future trends of TACE in patients with HCC.

This publication has 84 references indexed in Scilit: